ClinicalTrials.Veeva

Menu

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Gilead Sciences logo

Gilead Sciences

Status and phase

Enrolling
Phase 2

Conditions

Solid Tumor

Treatments

Drug: Sacituzumab Govitecan-hziy

Study type

Interventional

Funder types

Industry

Identifiers

NCT05119907
CTR20210912 (Other Identifier)
EVER-132-003

Details and patient eligibility

About

The goal of this study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with solid tumor.

Full description

Only Cohort C: Cervical Cancer (CC) is enrolling at this time.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

  • Histologically or cytologically-documented, incurable locally advanced or metastatic solid tumor of one of the following types:

    • Cohort A: oesophageal squamous-cell carcinoma that was refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy.
    • Cohort B: gastric adenocarcinoma that was refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy.
    • Cohort C: cervical cancer that was refractory or intolerant to platinum-based and taxane-based chemotherapy.
    • Cohort D: biliary tract cancer, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder cancer (GBC), with exception of ampullary carcinoma, progressed during or after first line platinum-based or fluoropyrimidine-based chemotherapy.
    • Cohort E: lung adenocarcinoma with activating genomic alterations (EGFR/ ALK/ ROS1/ BRAF/ MET/ RET) that was refractory or intolerant to targeted tyrosine kinase inhibitors (TKIs) and had not received platinum-based chemotherapy for unresectable local advanced or metastatic disease, and no suitable or willing to receive platinum-based chemotherapy.
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with RECIST v 1.1, bone-only disease is not measurable and is not permitted.

  • Availability of archival tumor tissue or newly acquired biopsy (unstaining tumor slides, recommended from metastasis sites).

  • Adequate bone marrow, hepatic and renal function.

  • Recovered from all prior treatment-related toxicities to Grade 1 or less by NCI-CTCAE v 5.0 (except alopecia or peripheral neuropathy that may be Grade 2 or less).

  • Individuals must have completed all prior cancer treatments at least 2 weeks prior to the first dose including chemotherapy , radiotherapy and major surgery. Prior antibody treatment for cancer must have been completed at least 3 weeks prior to the first dose.

  • Individuals must have at least a 3-month life expectancy.

Key Exclusion Criteria:

  • Previous treatment with topoisomerase I inhibitors as a free form or as other formulations.
  • Previous treatment with Trop-2 targeted therapy.
  • Individuals with a history of or current central nervous system (CNS) metastases.
  • Known additional malignancy within 3 years prior to enrollment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers.
  • Individuals known to be human immunodeficiency virus positive.
  • Individuals with active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Hepatitis B core antibody (HBcAb) testing is required and if positive, then HBV DNA testing will be performed and if positive the individual will be excluded.
  • Known history of unstable angina, myocardial infarction (MI), or chronic heart failure present within 6 months of first dose or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy or left ventricular ejection fraction < 50%.
  • Known history of clinically significant active chronic obstructive pulmonary disease, or other moderate-to-severe chronic respiratory illness present within 6 months of the first dose.
  • Infection requiring systematic antibiotic use within 1 week of the first dose.
  • Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal (GI) perforation.
  • High dose systemic corticosteroids within 2 weeks prior to the first dose (however, low dose corticosteroids ≤ 10 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks).
  • Individuals who have received a live vaccine within 30 days of first dose.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

300 participants in 5 patient groups

Cohort A: Esophageal Squamous Cell Carcinoma (ESCC)
Experimental group
Description:
Participants will receive Sacituzumab Govitecan-hziy (SG) 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
Treatment:
Drug: Sacituzumab Govitecan-hziy
Cohort B: Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJC)
Experimental group
Description:
Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
Treatment:
Drug: Sacituzumab Govitecan-hziy
Cohort C: Cervical Cancer (CC)
Experimental group
Description:
Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
Treatment:
Drug: Sacituzumab Govitecan-hziy
Cohort D: Biliary Tract Cancer (BTC)
Experimental group
Description:
Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
Treatment:
Drug: Sacituzumab Govitecan-hziy
Cohort E: Lung Adenocarcinoma (LAC)
Experimental group
Description:
Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
Treatment:
Drug: Sacituzumab Govitecan-hziy

Trial contacts and locations

13

Loading...

Central trial contact

Gilead Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems